全文获取类型
收费全文 | 210554篇 |
免费 | 16176篇 |
国内免费 | 5362篇 |
专业分类
耳鼻咽喉 | 1621篇 |
儿科学 | 3137篇 |
妇产科学 | 3509篇 |
基础医学 | 28588篇 |
口腔科学 | 4973篇 |
临床医学 | 14383篇 |
内科学 | 28529篇 |
皮肤病学 | 2952篇 |
神经病学 | 14213篇 |
特种医学 | 7016篇 |
外国民族医学 | 7篇 |
外科学 | 18142篇 |
综合类 | 28175篇 |
现状与发展 | 29篇 |
一般理论 | 10篇 |
预防医学 | 16130篇 |
眼科学 | 2865篇 |
药学 | 28695篇 |
58篇 | |
中国医学 | 13543篇 |
肿瘤学 | 15517篇 |
出版年
2024年 | 324篇 |
2023年 | 2831篇 |
2022年 | 4714篇 |
2021年 | 8894篇 |
2020年 | 7284篇 |
2019年 | 7493篇 |
2018年 | 7493篇 |
2017年 | 8038篇 |
2016年 | 7932篇 |
2015年 | 7720篇 |
2014年 | 9094篇 |
2013年 | 13132篇 |
2012年 | 10772篇 |
2011年 | 12983篇 |
2010年 | 8710篇 |
2009年 | 8630篇 |
2008年 | 10114篇 |
2007年 | 10920篇 |
2006年 | 10266篇 |
2005年 | 9467篇 |
2004年 | 8162篇 |
2003年 | 7193篇 |
2002年 | 5625篇 |
2001年 | 5000篇 |
2000年 | 4264篇 |
1999年 | 3631篇 |
1998年 | 2857篇 |
1997年 | 2884篇 |
1996年 | 2647篇 |
1995年 | 2283篇 |
1994年 | 2172篇 |
1993年 | 1841篇 |
1992年 | 1668篇 |
1991年 | 1575篇 |
1990年 | 1363篇 |
1989年 | 1111篇 |
1988年 | 1059篇 |
1987年 | 953篇 |
1986年 | 863篇 |
1985年 | 1342篇 |
1984年 | 1109篇 |
1983年 | 831篇 |
1982年 | 869篇 |
1981年 | 712篇 |
1980年 | 686篇 |
1979年 | 582篇 |
1978年 | 360篇 |
1977年 | 313篇 |
1976年 | 282篇 |
1975年 | 223篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
81.
淋巴管作为循环系统的重要组成部分之一,具有调节机体体液稳态,协助免疫监视和肠道脂质吸收等重要作用。淋巴管新生是机体生理和病理过程中维持脉管系统结构和功能正常的重要手段,淋巴管新生调控对于防治肿瘤、心血管等诸多疾病有着潜在的临床转化意义;淋巴回流功能则与关节炎症等疾病发病机制关系密切。在循环系统中,相较于中医药调控血管相关疾病的发病机制已取得很大进展,近年来对于淋巴管的研究则明显相对滞后。本文从中医药作用于淋巴管新生及回流功能角度对这一领域的研究进展作一综述,以期为临床上中医药治疗相关疾病提供新的思路与方法。 相似文献
82.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
83.
84.
miR-30c has been acknowledged as a tumor suppressor in various human cancers, such as ovarian cancer, gastric cancer, and prostate cancer. However, the role of miR-30c in glioblastoma (GBM) needs to be investigated.
In our study, we found that the expression of miR-30c was significantly downregulated in GBM tissues and
cell lines. We found that overexpression of miR-30c inhibited cellular proliferation of GBM cells in vitro and
in vivo. More GBM cells were arrested in the G0 phase after miR-30c overexpression. Moreover, we showed
that miR-30c overexpression suppressed the migration and invasion of GBM cells. Mechanistically, we found
that SOX9 was a direct target of miR-30c in GBM cells. Overexpression of miR-30c inhibited the mRNA
and protein levels of SOX9 in GBM cells. Moreover, there was a negative correlation between the expression
of miR-30c and SOX9 in GBM tissues. Finally, we showed that restoration of SOX9 in GBM cells reversed
the proliferation, migration, and invasion of GBM cells transfected with miR-30c mimic. Collectively, our
results demonstrated that miR-30c suppressed the proliferation, migration, and invasion of GBM cells via
targeting SOX9. 相似文献
85.
《Drug discovery today》2022,27(6):1733-1742
Compounds that exhibit assay interference or undesirable mechanisms of bioactivity are routinely encountered in assays at various stages of drug discovery. We observed that assays for the investigation of thiol-reactive and redox-active compounds have not been collected in a comprehensive review. Here, we review these assays and subject them to experimental optimization to improve their reliability. We demonstrate the usefulness of our assay cascade by assaying a library of bioactive compounds, chemical probes, and a set of approved drugs. These high-throughput assays should complement the array of wet-lab and in silico assays during the initial stages of hit discovery campaigns to pursue only hit compounds with tractable mechanisms of action. 相似文献
86.
目的 探讨糖尿病前期的中医证型及证素分布特点。方法 检索中国知网、万方及维普三大数据库中收录的自建库以来有关糖尿病前期证型的临床研究文献,对中医证型进行规范整理,建立数据库,提取证素,运用数据挖掘技术中的关联分析、聚类分析探究证素分布规律。结果 共纳入10篇文献,总有效病例1620例,证型经规范处理后整理为18个,主要证型为脾虚痰湿证。共提取证素13个,主要病位证素为脾,主要病性证素为气虚、湿和痰,关联分析显示脾—湿支持度和置信度最高,聚类分析结果可得到3个聚类组。结论 糖尿病前期病位在脾,气虚、脾、痰、湿是常见证素,临床诊治糖尿病前期应注重从脾论治,需辨证施治。 相似文献
87.
《European journal of surgical oncology》2022,48(2):326-332
BackgroundIn patients with melanoma, sentinel lymph node (SLN) status is pivotal for treatment decisions. Current routine for SLN detection combines Technetium99m (Tc99) lymphoscintigraphy and blue dye (BD). The primary aim of this study was to examine the feasibility of using a low dose of superparamagnetic iron oxide (SPIO) injected intracutaneously to detect and identify the SLN, and the secondary aim was to investigate if a low dose of SPIO would enable a preoperative MRI-evaluation of SLN status.MethodsPatients with melanoma of the extremities were eligible. Before surgery, a baseline MRI of the nodal basin was followed by an injection of a low dose (0.02–0.5 mL) of SPIO and then a second MRI (SPIO-MRI). Tc99 and BD was used in parallel and all nodes with a superparamagnetic and/or radioactive signal were harvested and analyzed.ResultsFifteen patients were included and the SLNB procedure was successful in all patients (27 SLNs removed). All superparamagnetic SLNs were visualized by MRI corresponding to the same nodes on scintigraphy. Micrometastatic deposits were identified in four SLNs taken from three patients, and SPIO-MRI correctly predicted two of the metastases. There was an association between MRI artefacts in the lymph node and the dose SPIO given.DiscussionIt is feasible to detect SLN in patients with melanoma using a low dose of SPIO injected intracutaneously compared with the standard dual technique. A low dose of SPIO reduces the lymph node MRI artefacts, opening up for a non-invasive assessment of SLN status in patients with cancer. 相似文献
88.
89.
Sarah Hallas Andrea Nelson Susan O'Meara Una Adderley Pauline Meskell Jane Nixon Aonghus O'Loughlin Sebastian Probst Wael Tawfick Thomas Wild Georgina Gethin 《Journal of tissue viability》2021,30(3):317-323
BackgroundA venous leg ulcer is a chronic leg wound caused by poor venous blood circulation in the lower limbs. It is a recurring condition causing pain, malodour, reduced mobility, and depression. Randomised controlled trials evaluating treatments for venous leg ulcers provide important evidence to inform clinical decision-making. However, for findings to be useful, outcomes need to be clinically meaningful, consistently reported across trials, and fully reported. Research has identified the large number of outcomes reported in venous leg ulcer trials, impacting both synthesis of results, and clinical decision-making. To address this, a core outcome set will be developed. A core outcome set is an agreed standardised set of outcomes which should be, as a minimum, measured and reported in all trials which evaluate treatment effectiveness for a given indication. A core outcome set has the potential to reduce research waste, improve the utility of RCTs, reduce reporting bias, facilitate treatment comparisons across different sources of evidence and expedite the production of systematic reviews, meta-analyses and evidence-based clinical guidelines.AimThe aim of this project is to develop a core outcome set for research evaluating the effectiveness of interventions for treating venous leg ulceration.MethodsThrough a scoping review of the literature on venous leg ulceration, we will firstly identify a list of candidate outcome domains (broad categories in relation to what is being measured) from randomised controlled trials and qualitative research, and outcomes (specific methods in relation to what is being measured). In two further stages, we will use the resulting lists of outcome domains and outcomes to design two online surveys. A range of stakeholders will be invited to participate in the surveys and they will be asked to indicate which outcome domains and outcomes are most important and should be considered as core in future research reports. 相似文献
90.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献